Therefore, beyond inhibition of viral replication, PAV-104 may exert adjunctive anti-inflammatory effects via selective suppression of IFN pathway members that enhances its clinical potential as a therapeutic for COVID-19. The gene discussed is IFNA1; the disease is COVID-19.